A key concern with the administration of CCR5 blockers in-vivo relates to the emergence of CXCR4 (X4) tropic virus [1], which is associated with worse clinical outcomes than CCR5 (R5) tropic virus and with faster clinical progression to AIDS [13], [14], [15]. Here, CCR5 is linked to AIDS.